Rezafungin PK in Patients on ECMO - Trial NCT06329518
Access comprehensive clinical trial information for NCT06329518 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hartford Hospital and is currently Not yet recruiting. The study focuses on Sepsis. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hartford Hospital
Timeline & Enrollment
Phase 1
Apr 01, 2024
Apr 01, 2025
Primary Outcome
Rezafungin Clearance
Summary
Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for
 critically ill patients where blood is extracted from the vascular system and circulated by a
 mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is
 well known that critically ill patients may experience alterations in antibiotic
 pharmacokinetics, and as a result, dosing modifications are generally required. There is a
 need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs.
 This study is designed to assess the pharmacokinetics of the new broad-spectrum echinocandin,
 Rezafungin, in critically ill patients receiving ECMO
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06329518
Non-Device Trial